Showing results (51-60 of 58) with videos related to
Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 58 results.
American Journal of Clinical Dermatology|September 19, 2025
Systemic Treatments in Moderate-to-Severe Atopic Dermatitis in Pediatric Patients up to 12 Years of Age: Real-World Treatment Outcomes from the PEDISTAD RegistryAmy S Paller, Danielle Marcoux, Michele Ramien, et al.Journal of the American Academy of Dermatology|October 10, 2024
Real-world treatment outcomes of systemic treatments for moderate-to-severe atopic dermatitis in children aged less than 12 years: 2-year results from PEDIatric STudy in Atopic DermatitisAmy S Paller, Marjolein de Bruin-Weller, Danielle Marcoux, et al.The Journal of Allergy and Clinical Immunology|January 25, 2025
Longitudinal integrated proteomic and metabolomic skin changes in patients with atopic dermatitis treated with dupilumabElena Goleva, Evgeny Berdyshev, Simion Kreimer, et al.Dermatology and Therapy|April 17, 2026
Summary of Research: Systemic Treatments in Moderate-to-Severe Atopic Dermatitis in Pediatric Patients up to 12 Years of Age: Real-World Treatment Outcomes from the PEDISTAD RegistryAmy S Paller, Danielle Marcoux, Michele Ramien, et al.Journal of the American Academy of Dermatology|July 7, 2026
Dupilumab treatment improves linear growth and bone biomarkers in children with atopic dermatitis: Post hoc analysis of a phase 3 randomized, placebo-controlled clinical trial and an open-label extension studyAlan D Irvine, Amy S Paller, Elaine C Siegfried, et al.Annals of Clinical and Translational Neurology|April 25, 2015
Comparative efficacy of switching to natalizumab in active multiple sclerosisTimothy Spelman, Tomas Kalincik, Annie Zhang, et al.Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|January 29, 2026
Dupilumab treatment restores epithelial barrier in nonlesional and lesional skin in children with atopic dermatitisMichael J Cork, Peck Y Ong, Simon G Danby, et al.Neurology. Clinical Practice|April 23, 2016
Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MSTim Spelman, Tomas Kalincik, Vilija Jokubaitis, et al.Pageof 6